MED-PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MED-PHARMA
Largest movements
- Receivables within one year -€93,858
down €93,858 (-94.0%), from €99,811 to €5,953
of which Other amounts receivable: -€81,673
- Deferred charges and accrued income -€11,173
no longer reported in 2025 (was €11,173)
- Other debts -€112,371
down €112,371 (-53.7%), from €209,185 to €96,814
- Profit (loss) carried forward +€33,279
up €33,279 (+4.6%), from €729,030 to €762,309
- Gross operating margin +€8,044
up €8,044 (+26.4%), from €30,510 to €38,554
- Taxes +€4,450
up €4,450 (+47.4%), from €9,383 to €13,833
- Financial charges -€1,658
down €1,658 (-30.4%), from €5,444 to €3,787
- Financial income +€790
up €790 (+5.7%), from €13,859 to €14,649
- Other operating charges +€541
up €541 (+44.5%), from €1,216 to €1,757
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €983,914 | €892,951 | -€90,963 | -9.2% |
| Fixed assets | 21/28 | €706,533 | €706,746 | +€213 | 0.0% |
| Tangible fixed assets | 22/27 | €924 | €1,137 | +€213 | +23.0% |
| Land and buildings | 22 | €924 | - | -€924 | |
| Plant, machinery and equipment | 23 | - | €280 | +€280 | |
| Furniture and vehicles | 24 | - | €395 | +€395 | |
| Other tangible fixed assets | 26 | - | €462 | +€462 | |
| Financial fixed assets | 28 | €705,609 | €705,609 | = | 0.0% |
| Current assets | 29/58 | €277,381 | €186,205 | -€91,175 | -32.9% |
| Amounts receivable after more than one year | 29 | €166,396 | €175,664 | +€9,268 | +5.6% |
| Other amounts receivable | 291 | €166,396 | €175,664 | +€9,268 | +5.6% |
| Amounts receivable within one year | 40/41 | €99,811 | €5,953 | -€93,858 | -94.0% |
| Trade receivables | 40 | €12,185 | - | -€12,185 | |
| Other amounts receivable | 41 | €87,626 | €5,953 | -€81,673 | -93.2% |
| Cash at bank and in hand | 54/58 | - | €4,588 | +€4,588 | |
| Deferred charges and accrued income | 490/1 | €11,173 | - | -€11,173 | |
| Total equity and liabilities | 10/49 | €983,914 | €892,951 | -€90,963 | -9.2% |
| Equity | 10/15 | €743,290 | €776,569 | +€33,279 | +4.5% |
| Contributions | 10/11 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €1,860 | €1,860 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,860 | €1,860 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,860 | €1,860 | = | 0.0% |
| Profit (loss) carried forward | 14 | €729,030 | €762,309 | +€33,279 | +4.6% |
| Amounts payable | 17/49 | €240,624 | €116,382 | -€124,242 | -51.6% |
| Amounts payable after more than one year | 17 | - | €1,818 | +€1,818 | |
| Financial debts | 170/4 | - | €1,818 | +€1,818 | |
| Amounts payable within one year | 42/48 | €239,657 | €114,565 | -€125,092 | -52.2% |
| Current portion of amounts payable after more than one year | 42 | - | €7,075 | +€7,075 | |
| Financial debts | 43 | €15,941 | €8,971 | -€6,970 | -43.7% |
| Credit institutions | 430/8 | €15,941 | €8,971 | -€6,970 | -43.7% |
| Trade debts | 44 | €5,684 | €872 | -€4,812 | -84.7% |
| Suppliers | 440/4 | €5,684 | €872 | -€4,812 | -84.7% |
| Taxes, remuneration and social security | 45 | €8,846 | €833 | -€8,013 | -90.6% |
| Taxes | 450/3 | €8,846 | €833 | -€8,013 | -90.6% |
| Other amounts payable | 47/48 | €209,185 | €96,814 | -€112,371 | -53.7% |
| Accrued charges and deferred income | 492/3 | €968 | - | -€968 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €462 | €547 | +€85 | +18.3% |
| Other operating charges | 640/8 | €1,216 | €1,757 | +€541 | +44.5% |
| Gross operating margin | 9900 | €30,510 | €38,554 | +€8,044 | +26.4% |
| Operating profit (loss) | 9901 | €28,832 | €36,250 | +€7,418 | +25.7% |
| Financial income | 75/76B | €13,859 | €14,649 | +€790 | +5.7% |
| Recurring financial income | 75 | €13,859 | €14,649 | +€790 | +5.7% |
| Financial charges | 65/66B | €5,444 | €3,787 | -€1,658 | -30.4% |
| Recurring financial charges | 65 | €5,444 | €3,787 | -€1,658 | -30.4% |
| Profit (loss) for the period before taxes | 9903 | €37,246 | €47,112 | +€9,866 | +26.5% |
| Income taxes | 67/77 | €9,383 | €13,833 | +€4,450 | +47.4% |
| Profit (loss) for the period | 9904 | €27,863 | €33,279 | +€5,416 | +19.4% |
| Profit (loss) for the period to be appropriated | 9905 | €27,863 | €33,279 | +€5,416 | +19.4% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.